SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : Pharmos(PARS)
PARS 2.700+13.6%Jan 21 4:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: NeuroInvestment who wrote (923)6/26/1998 5:09:00 PM
From: Tony van Werkhooven   of 1491
 
You have me intrigued. What options are being looked at?

Here are the possible options that I see:

Option 1: Market through B&L sales force- requires a learning curve for the allergy market

Option 2: Depend on advertising and mailings to "spread the word"

Option 3: Find a partner who currently markets to allergy practitioners.

On the surface, it seems that options 1 and 2 are detrimental to Pharmos- much slower sales curve, perhaps never reach its potential.

Why would Pharmos consider options 1 or 2? Are there other options to be considered?

Thanks

Tony
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News